PMA device
FlexNav and Navitor Loading System, FlexNav Delivery System
Abbott Medical · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Oct 1, 2024, newest Oct 1, 2024Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
8
Naming "FlexNav"
MAUDE reports
746
Brand "FlexNav", since 2015
PubMed studies
13
Mentioning "FlexNav"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FlexNav and Navitor Loading System, FlexNav Delivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P190023-S020 · Decided Oct 1, 2024 · 71 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "FlexNav", any status and sponsor, newest update first.
- Portico Next Generation Approval StudyActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT04011722 · 333 participants · Start Sep 17, 2019 · Primary completion Jan 12, 2023
Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System; Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System · For: Symptomatic Severe Aortic Stenosis
Sites: Los Angeles, California; Thousand Oaks, California; Washington D.C., District of Columbia · 28 sites in all
Abbott Medical DevicesPublic (ABT)
NCT06008080 · 1,000 participants (planned) · Start Sep 29, 2023 · Primary completion Jul 2027
Device: Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System · For: Aortic Stenosis
Sites: Adelaide, Australia; Hobart, Australia; Melbourne, Australia · 50 sites in all
- Navitor Japan StudyRecruiting
Abbott Medical DevicesPublic (ABT)
NCT07193888 · 100 participants (planned) · Start Oct 30, 2025 · Primary completion Jul 2028
Device: Navitor Transcatheter Aortic Valve Implantation · For: Severe Aortic Stenosis
Sites: Fukuoka, Japan; Kanagawa, Japan; Osaka, Japan
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FlexNav", and for the whole product code for context.
This brand
746 reports: 423 malfunction, 289 injury, 34 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
- FlexNav Delivery SystemInjury
2135147-2026-07257 · Received Oct 28, 2026 · Event dated Oct 1, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding
- FlexNav Delivery SystemInjury
2135147-2026-07175 · Received Oct 26, 2026 · Event dated Sep 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Device Damaged by Another Device; Difficult to Advance
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Vascular Dissection
- FlexNav Delivery SystemMalfunction
2135147-2026-07135 · Received Oct 23, 2026 · Event dated Sep 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Retraction Problem; Device Damaged by Another Device; Material Deformation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Abbott Navitor Titan, Vision Technology, Transcatheter Aortic Heart Valve, 35 mm, NVRO-35, SterileOpen, Classified
Z-0491-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0492-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
- Abbot Navitor, Vision Technology, Transcatheter Aortic Heart Valve, 29 mm, NVRO-29, SterileOpen, Classified
Z-0493-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
2 more recall records with a free account
Published research
The most relevant PubMed records for "FlexNav"[tiab]. The summary above synthesizes these.
- Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System.
Fontana GP, Bedogni F, Groh M, et al. · JACC Cardiovasc Interv · 2020Multicenter Study
- Combined transcatheter aortic valve and tricuspid valve-in-valve implantation in a patient with a mitral mechanical prosthesis.
Lima MR, Brito J, Almeida M, et al. · Catheter Cardiovasc Interv · 2024Case Reports
- Valve Hemodynamics by Valve Size and 1-Year Survival Following Implantation of the Portico Valve in the Multicenter CONFIDENCE Registry.
Möllmann H, Linke A, Nombela-Franco L, et al. · Struct Heart · 2024
- Procedural Safety and Device Performance of the Porticoࡊ Valve from Experienced TAVI Centers: 30-Day Outcomes in the Multicenter CONFIDENCE Registry.
Mollmann H, Linke A, Nombela-Franco L, et al. · J Clin Med · 2022
- 30-Day Outcomes With the Portico Transcatheter Heart Valve: Insights From a Multi-Centre Australian Observational Study.
Camuglia AC, Cole CMW, Boyne N, et al. · Heart Lung Circ · 2023Observational Study, Multicenter Study
- Cusp-overlap technique during TAVI using the self-expanding Portico FlexNav system.
Asmarats L, Gutiérrez-Alonso L, Nombela-Franco L, et al. · Rev Esp Cardiol (Engl Ed) · 2023
- Real-Life Performance and Clinical Outcomes of Portico Transcatheter Aortic Valve with FlexNav Delivery System: One-Year Data from a Single-Center Experience.
Yildirim A, Genc O, Pacaci E, et al. · J Clin Med · 2023
- In-hospital outcomes of Portico transcatheter aortic valve replacement with the FlexNav as compared to the first-generation delivery system.
Rigattieri S, Marino G, Giovannelli F, et al. · Postepy Kardiol Interwencyjnej · 2023
- Improved transfemoral accessibility and positioning of the Portico transcatheter heart valve with the new FlexNav delivery system.
Casenghi M, Rubbio AP, Marco F, et al. · Future Cardiol · 2021
- TAVR With the Novel Navitor Titanࡊ Transcatheter Heart Valve to Treat Aortic Stenosis Patients With Large Aortic Annuli.
Bajoras V, Nuyens P, Vanhaverbeke M, et al. · Cardiovasc Revasc Med · 2022Case Reports
- One-Year Results of the Portico Transcatheter Aortic Heart Valve Using the Next-Generation FlexNav Delivery System.
Fontana GP, Bedogni F, Groh M, et al. · J Soc Cardiovasc Angiogr Interv · 2023
- The Novel FlexNav Delivery System for Transcatheter Aortic Valve Implantation With the Portico Device: A Case Series.
Corcione N, Morello A, Ferraro P, et al. · J Invasive Cardiol · 2021Case Reports
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.